3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Lung Neoplasms
1
Lung Diseases
1
Interventions
Carboplatin
66
Cisplatin
57
Paclitaxel
42
Radiotherapy
35
Pemetrexed
34
Gemcitabine
31
Docetaxel
31
Etoposide
24
pembrolizumab
21
Vinorelbine
20
Erlotinib Hydrochloride
13
Magnetic Resonance Spectroscopy
12
Gefitinib
11
Specimen Handling
10
Radiosurgery
10
Drug Therapy
10
Bevacizumab
10
durvalumab
9
Nivolumab
9
Vinblastine
6
Topotecan
6
Surgical Procedures, Operative
6
Cyclophosphamide
6
Standard of Care
5
Platinum
5
Immunoglobulin G
5
Ifosfamide
5
Disulfides
5
Dexamethasone
5
paclitaxel poliglumex
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lung Neoplasms
×
zipalertinib
×
Clear all
NCT07128199
2026-05-05
REZILIENT4
Taiho Oncology, Inc.
Phase 3
Active not recruiting
360 enrolled